University of Maryland and BioGenCell Announce the Launch of BioGenCell Fifth Chronic Limb-Threatening Ischemia Clinical Trial Site in the United States

BioGenCell has announced the inauguration of the fifth Phase II cell-therapy-based clinical trial site for Chronic Limb-Threatening Ischemia (CLTI) in the United States at the University of Maryland, Baltimore. This initiative is committed to dramatically reducing the incidence of amputations in patients afflicted with severe CLTI. BALTIMORE, Dec. 7, 2023 /PRNewswire/ — BioGenCell, a pioneer … Read more